In a mouse study, UCLA researchers tested a vaccine against the bacterium that causes melioidosis and found it was highly protective against the disease, which is endemic in many tropical areas, causing approximately 165,000 cases with 89,000 fatalities around the world each year.
To date there are no licensed vaccines against the bacterium, said senior author Dr. Marcus Horwitz, Distinguished Professor of Medicine, in the division of infectious diseases, and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at UCLA.
A safe and effective vaccine is needed to prevent this disease as melioidosis is often difficult to diagnose, requires very lengthy treatment lasting three to six months, and has a high fatality rate even in high resource settings.Dr. Marcus Horwitz, Distinguished Professor of Medicine, Division of infectious diseases, and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at UCLA
The bacterium, called Burkholderia pseudomallei, is spread through contact with contaminated soil and water through inhalation, ingestion or broken skin. It is so dangerous that it is categorized as a Tier 1 Select Agent of bioterrorism, and it can cause rapidly fatal pneumonia when inhaled in low doses. If aerosolized and unleashed in a terror attack, it could lead to widespread death.
The researchers developed the vaccine using a bacterial vector called LVS ΔcapB as a platform to express highly immunogenic proteins from B. pseudomallei that are able to induce an immune response that later protects the host from illness and death when infected with the pathogen. LVS ΔcapB, derived from a weakened form of a vaccine against tularemia, or “rabbit fever,” had been developed in Horwitz’s lab as a vector platform for creation of vaccines against other diseases caused by Tier 1 Select Agents such as anthrax and plague as well as tularemia.
They administered the new vaccine through both skin injection and intranasal delivery in a strain of mice that is particularly sensitive to B. pseudomallei lung infection. The researchers found that the vaccine was not only safe and non-toxic, but effective even against a highly lethal strain of the melioidosis bacteria. Intranasal administration provided better protection than skin injection, with just a single dose proving effective with long-lasting protection.
The next steps are to test the vaccine for protection against pneumonic melioidosis in a second animal model, which the Food and Drug Administration requires in the case of vaccines for which human efficacy studies cannot be conducted. If it passes that test, the vaccine would then become eligible for testing in humans for safety and immunogenicity S. The researchers will also evaluate the vaccine’s effectiveness against subcutaneous infection with B. pseudomallei, which is the way most cases of melioidosis are thought to be acquired naturally, and test it for efficacy against the closely related Tier 1 Select Agent pathogen Burkholderia mallei, which causes glanders in humans and animals.
(Newswise/AP)